SolarWindow (WNDW) POS AM 23 Feb 21 Prospectus update (post-effective amendment) Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Nov. 30, 2020
Document And Entity Information
Entity Registrant Name	SolarWindow Technologies, Inc.
Entity Central Index Key	0001071840
Document Type	POS AM
Amendment Flag	true
Amendment Description	On February 2, 2018, the registrant filed a registration statement on Form S-1 (Registration No. 333-222809) (the “Combined Registration Statement”), which contained, pursuant to Rule 429 under the Securities Act of 1933, a combined prospectus relating to (i) the initial registration of an aggregate of 1,643,200 shares for resale and (ii) the registration for resale of an aggregate of 1,527,445 shares of the 4,317,500 shares that were previously registered pursuant to the Registrant’s Registration Statement (No. 333-212770) previously filed by the Registrant on Form S-1 on July 29, 2016 and declared effective by the Securities and Exchange Commission on August 18, 2016, as amended by Post-Effective Amendment No. 1 filed on November 28, 2016 and declared effective on November 30, 2016 and which related to the resale of up to 4,317,500 shares of common stock of the Registrant from time to time by the Selling Stockholders named therein (the “Prior Registration Statement”). An aggregate of 2,790,055 registered under the Prior Registration Statement were removed from registration at the request of the Selling Stockholders owning the same. This Amendment constitutes Post-effective Amendment No. 3 to the Combined Registration Statement, and Post-Effective Amendment No. 3 to the Prior Registration Statement. It also (i) removes from registration an additional 2,003,445 shares and (ii) updates the financial statements contained in the Registration Statement as well as certain of the narrative discussion contained therein.
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Incorporation, State or Country Code	NV

CONSOLIDATED BALANCE SHEETS (UN

CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Current assets
Cash and cash equivalents	$ 8,549,510	$ 14,151,523	$ 16,604,011
Short-term investments	5,000,000
Deferred research and development costs	463,614	574,731	580,879
Prepaid expenses and other current assets	20,962	56,147	46,832
Total current assets	14,034,086	14,782,401	17,231,722
Operating lease right-of-use asset		42,212	65,646
Property and equipment, net of accumulated depreciation of $88,498 and $93,323, respectively	1,360,503	1,349,495	1,368,929
Security deposit	13,537	2,200	2,200
Total assets	15,408,126	16,176,308	18,668,497
Current liabilities
Accounts payable and accrued expenses	64,256	53,428	97,549
Related party payables	71,967	113,186	57,933
Current maturities of operating lease		24,828	23,169
Total current liabilities	136,223	191,442	178,651
Non-current operating lease		17,737	42,564
Total long term liabilities		17,737	42,564
Total liabilities	136,223	209,179	221,215
Commitments and contingencies
Stockholders' equity
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.001 par value; 300,000,000 shares authorized, 52,959,323 shares issued and outstanding at November 30, 2020 and August 31, 2020	52,959	52,959	52,959
Additional paid-in capital	77,877,741	76,039,209	71,166,300
Accumulated other comprehensive income (loss)	3,277
Retained deficit	(62,662,074)	(60,125,039)	(52,771,977)
Total stockholders' equity	15,271,903	15,967,129	18,447,282
Total liabilities and stockholders' equity	$ 15,408,126	$ 16,176,308	$ 18,668,497

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Current assets
Equipment, net of accumulated depreciation	$ 88,498	$ 93,323	$ 68,858
Stockholders' equity (deficit)
Preferred stock, par value	$ 0.10	$ 0.10	$ 0.10
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, shares issued	52,959,323	52,959,323	52,959,323
Common stock, shares outstanding	52,959,323	52,959,323	52,959,323

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Consolidated Statements Of Operations
Revenue
Operating expenses
Selling, general and administrative	1,999,785	620,781	5,323,579	4,431,643
Research and product development	547,864	579,000	2,279,884	1,979,222
Total operating expenses	2,547,649	1,199,781	7,603,463	6,410,865
Loss from operations	(2,547,649)	(1,199,781)	(7,603,463)	(6,410,865)
Other income (expense)
Interest income	19,389	94,503	250,401	315,344
Loss on disposal of assets	(8,775)
Interest expense				(128,239)
Accretion of debt discount				(663,918)
Total other income (expense)	10,614	94,503	250,401	(476,813)
Net loss	$ (2,537,035)	$ (1,105,278)	$ (7,353,062)	$ (6,887,678)
Basic and Diluted Loss per Common Share	$ (0.05)	$ (0.02)	$ (0.14)	$ (0.14)
Weighted average number of common shares outstanding - basic and diluted	52,959,323	52,959,323	52,959,323	48,686,720

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)	3 Months Ended
	Nov. 30, 2020	Nov. 30, 2019
Consolidated Statements Of Comprehensive Income
Net income (loss)	$ (2,537,035)	$ (1,105,278)
Other comprehensive income (loss):
Foreign currency translation adjustments	3,277
Comprehensive income (loss)	$ (2,533,758)	$ (1,105,278)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Cash flows from operating activities
Net loss	$ (2,537,035)	$ (1,105,278)	$ (7,353,062)	$ (6,887,678)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation	5,782	6,684	24,465	18,349
Stock based compensation expense	1,838,532	420,970	4,872,909	3,959,367
Loss on disposal of assets	8,775
Security deposits	(10,890)			(2,200)
Accretion of debt discount				663,918
Changes in operating assets and liabilities:
Deferred research and development costs	111,117	(77,706)	6,148	(446,904)
Prepaid expenses and other assets	35,185	20,047	(9,315)	11,987
Accounts payable and accrued expenses	10,792	25,700	(44,121)	3,933
Operating lease assets and liabilities	(353)	68	266	87
Related party payable	(41,219)	61,047	55,253	57,933
Interest payable				76,057
Net cash flows from operating activities	(579,314)	(648,468)	(2,447,457)	(2,545,151)
Cash flows used in investing activity
Purchaseof short-term investments	(5,000,000)
Proceeds from the sale of assets	2,161
Purchase of equipment	(27,726)	(5,031)	(5,031)	(1,347,664)
Net cash flows used in investing activity	(5,025,565)	(5,031)	(5,031)	(1,347,664)
Cash flows from financing activities
Proceeds from the issuance of equity securities				19,800,000
Net cash flows from financing activities				19,800,000
Effect of exchange rate changes on cash and cash equivalents	2,866
Net increase (decrease) in cash and cash equivalents	(5,602,013)	(653,499)	(2,452,488)	15,907,185
Cash and cash equivalents at beginning of period	14,151,523	16,604,011	16,604,011	696,826
Cash and cash equivalents at end of period	8,549,510	15,950,512	14,151,523	16,604,011
Supplemental disclosure of cash flow information:
Interest paid in cash				52,182
Income taxes paid in cash
Supplemental disclosure of non-cash transactions:
Common stock issued for conversion of note payable				$ 5,200,000

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income	Total
Beginning Balance, Shares at Aug. 31, 2017	34,329,691
Beginning Balance, Amount at Aug. 31, 2017	$ 34,330	$ 35,363,946	$ (39,029,752)		$ (3,631,476)
September 2017 Private Placement units issued for cash, Shares	821,600
September 2017 Private Placement units issued for cash, Amount	$ 822	2,554,354			2,555,176
Stock based compensation related to stock issuances, Shares	210,000
Stock based compensation related to stock issuances, Amount	$ 210	1,022,490			1,022,700
Exercise of warrants for cash, Shares	119,500
Exercise of warrants for cash, Amount	$ 120	394,030			394,150
Exercise of warrants on a cashless basis, Shares	665,703
Exercise of warrants on a cashless basis, Amount	$ 665	(665)
Exercise of stock options on a cashless basis, Shares	146,162
Exercise of stock options on a cashless basis, Amount	$ 146	(146)
Stock based compensation due to common stock purchase options		1,815,325			1,815,325
Discount on convertible promissory note due warrant modifications		1,074,265			1,074,265
Net loss			(6,854,547)		(6,854,547)
Ending Balance, Shares at Aug. 31, 2018	36,292,656
Ending Balance, Amount at Aug. 31, 2018	$ 36,293	42,223,599	(45,884,299)		(3,624,407)
November 2018 Private Placement units issued for cash, Shares	13,200,000
November 2018 Private Placement units issued for cash, Amount	$ 13,200	19,786,800			19,800,000
November 2018 Private Placement units issued in exchange for convertible debt, Shares	3,466,667
November 2018 Private Placement units issued in exchange for convertible debt, Amount	$ 3,466	5,196,534			5,200,000
Stock based compensation due to common stock purchase options		3,959,367			3,959,367
Net loss			(6,887,678)		(6,887,678)
Ending Balance, Shares at Aug. 31, 2019	52,959,323
Ending Balance, Amount at Aug. 31, 2019	$ 52,959	71,166,300	(52,771,977)		18,447,282
Stock based compensation due to common stock purchase options		420,970			420,970
Net loss			(1,105,278)		(1,105,278)
Ending Balance, Shares at Nov. 30, 2019	52,959,323
Ending Balance, Amount at Nov. 30, 2019	$ 52,959	71,587,270	(53,877,255)		17,762,974
Beginning Balance, Shares at Aug. 31, 2019	52,959,323
Beginning Balance, Amount at Aug. 31, 2019	$ 52,959	71,166,300	(52,771,977)		18,447,282
Ending Balance, Shares at Aug. 31, 2020	52,959,323
Ending Balance, Amount at Aug. 31, 2020	$ 52,959	76,039,209	(60,125,039)		15,967,129
Stock based compensation due to common stock purchase options		1,838,532			1,838,532
Foreign currency translation adjustments				3,277	3,277
Net loss			(2,537,035)		(2,537,035)
Ending Balance, Shares at Nov. 30, 2020	52,959,323
Ending Balance, Amount at Nov. 30, 2020	$ 52,959	$ 77,877,741	$ (62,662,074)	$ 3,277	$ 15,271,903

Organization

Organization	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 1 - Organization	NOTE 1 – Basis of Presentation and Organization Basis of Presentation The accompanying unaudited interim consolidated financial statements of SolarWindow Technologies, Inc. (the “ Company U.S. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended August 31, 2020. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s consolidated financial position as of November 30, 2020, results of operations, stockholders’ equity and cash flows for the three months ended November 30, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Organization SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998. Products derived from the Company’s SolarWindow™ technology harvest light energy from the sun and from artificial light sources, by generating electricity from a transparent coating of organic photovoltaic (“ OPV Liquidity and Management’s Plan The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of November 30, 2020, the Company had $13,549,510 of cash and cash equivalents and short term investments on hand and working capital of $13,897,863. The Company believes that it currently has sufficient cash to meet its funding requirements over the next twelve months following the issuance of this Quarterly Report on Form 10-Q. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it may need to raise additional capital to accomplish its business plan. If additional funding is required, the Company expects to seek to obtain that funding through financial or strategic investors. There can be no assurance as to the availability or terms upon which such financing and capital might be available.	NOTE 1 – Organization SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998. Products derived from the Company’s SolarWindow™ technology harvest light energy from the sun and from artificial light sources, by generating electricity from a transparent coating of organic photovoltaic (“ OPV Photovoltaics are commonly known as “solar panels” providing a method to generate electricity using solar cells to convert energy from light into a flow of electrons. Conventional PV power is generated by solar modules composed of interconnected mono- or poly-crystalline cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., non-transparent) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with very thin layers of specially developed compounds that allow our SolarWindow™ technology to remain see-through or “transparent” while generating electricity when exposed to either sun or artificial light. SolarWindow™ coatings generate electricity when exposed to direct, diffused, filtered, low, or reflected natural or artificial light. The company has filed patent applications related to the application and fabrication of SolarWindow™ devices using these compounds. Liquidity and Management’s Plan The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of August 31, 2020, the Company had $14,151,523 of cash on hand and working capital of $14,590,959. The Company believes that it currently has sufficient cash to meet its funding requirements over the next twelve months following the issuance of this Annual Report on Form 10-K. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it may need to raise additional capital to accomplish its business plan over the next several years. If additional funding is required, the Company expects to seek to obtain that funding through financial or strategic investors. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 2 - Summary of Significant Accounting Policies	NOTE 2 – Summary of Significant Accounting Policies Information regarding the Company’s significant accounting policies is contained in Note 2, “Summary of significant accounting policies,” to the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended August 31, 2020. Presented below and in the following notes is supplemental information that should be read in conjunction with “Notes to Financial Statements” in the Annual Report. Fiscal quarter The Company’s quarterly periods end on November 30, February 28, May 31, and August 31. The Company’s first quarter in fiscal 2021 and 2020 ended on November 30, 2020 and 2019, respectively. Principles of consolidation On August 24, 2020, the Company formed wholly owned SolarWindow Asia (USA) Corp. as the holding company for SolarWindow Asia Co. Ltd., a company formed in the Republic of Korea for the purpose of expansion into the Asian markets. As of August 31, 2020, the Company had not capitalized the Korean subsidiaries and there were no transactions related to these entities during the year ended August 31, 2020. During our fiscal quarter ended November 30, 2020, the Company capitalized SolarWindow Asia Co. Ltd. with a transfer of $831,000. These consolidated financial statements presented are those of SolarWindow Technologies, Inc. and its wholly owned subsidiaries, SolarWindow Asia (USA) Corp., and SolarWindow Asia Co. Ltd. All significant intercompany balances and transactions have been eliminated. Use of estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the accounting period. The Company considers its accounting policies relating to stock based compensation to be the most significant accounting policy that involves management estimates and judgments. The Company has made accounting estimates based on the facts and circumstances available as of the reporting date. Actual amounts could differ from these estimates, and such differences could be material. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and highly liquid investments with original maturities of three months or less from the date of purchase. November 30, 2020 August 31, 2020 Cash and cash equivalents $ 8,549,510 $ 14,151,523 Short-term investment 5,000,000 - Cash and cash equivalents $ 13,549,510 $ 14,151,523 Short-term investments The Company determines the balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. Money market funds, certificates of deposit, and time deposits with maturities of greater than three months but no more than twelve months are carried at cost, which approximates fair value and are recorded in the consolidated balance sheets in short-term investments. As of November 30, 2020, the short-term investment consists of a fixed-term deposit with a twelve month maturity at the time of purchase on October 1, 2020. Recent accounting pronouncements not yet adopted In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. Recently adopted accounting pronouncements The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the consolidated financial statements.	NOTE 2 – Summary of Significant Accounting Policies Principles of Consolidation On July 5, 2019, the Board of Directors voted to dissolve Kinetic Energy Corporation (“KEC”) and New Energy Solar (“NES”). KEC was incorporated on June 19, 2008. NES was incorporated on February 9, 2009. Neither KEC nor NES had operating activity for the year ended August 31, 2019. On August 24, 2020, the Company formed wholly owned SolarWindow Asia (USA) Corp. as the holding company for SolarWindow Asia Co. Ltd., a company formed in the Republic of Korea for the purpose of expansion into the Asian markets. As of August 31, 2020, the Company had not capitalized the Korean subsidiaries and there were no transactions related to these entities during the year ended August 31, 2020. As a result, the financial statements presented are solely those of SolarWindow Technologies, Inc. Use of Estimates The preparation of the Company’s financial statements requires management to make estimates and use assumptions that affect the reported amounts of assets, liabilities and expenses. These estimates and assumptions are affected by management’s application of accounting policies. On an on-going basis, the Company evaluates its estimates. Actual results and outcomes may differ materially from these estimates and assumptions. Cash and Cash Equivalents The Company considers cash deposits to be cash and all highly liquid investment instruments with original maturities of 90 days or less when purchased, to be cash equivalents. Cash deposits are carried at cost which approximates their fair value. The Company had $14,151,523 of cash deposits as of August 31, 2020, including $282,042 in domestic bank accounts and $13,869,481 held in Canadian bank accounts in excess of Canadian Deposit Insurance Corporation insured limits. Leases The Company recognizes their leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating lease for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. Equipment Fixed assets are carried at cost, less accumulated depreciation. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in that period. Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives (in years) Computer equipment and software 3 Equipment, furniture and fixtures 5 Patent and Trademark Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Fair Value Measurements The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 1 inputs. Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 2 inputs. Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 3 inputs. Fair Value of Financial Instruments The carrying value of cash and accounts payable approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Research and Product Development Research and product development costs represent costs incurred to develop the Company’s technology, including salaries and benefits for research and development personnel, allocated overhead and facility occupancy costs, supplies, equipment purchase and repair and other costs. Research and product development costs are expensed when incurred, except for nonrefundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with Accounting Standards Codification (“ASC”) 718, Stock Based Compensation. ASC 718 requires all stock-based payments to directors, employees and consultants, including grants of stock options, to be recognized in the consolidated statements of operations based on their fair values. The Company uses the Black-Scholes option pricing model (the “ Black-Scholes Model The determination of the fair value of stock-based payment awards utilizing the Black-Scholes option pricing model requires the use of the following assumptions: expected volatility of our common stock, which is based on our own calculated historical rate; expected life of the option award, which we elected to calculate using the simplified method; expected dividend yield, which is 0%, as we have not paid and do not have any plans to pay dividends on our common stock; and the risk-free interest rate, which is based on the U.S. Treasury rate in effect at the time of grant with maturities equal to the stock option award’s expected life. The Company evaluates the assumptions used to value the awards at each grant date and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. Forfeitures are accounted for as they occur. See “NOTE 6 – Common Stock and Warrants” and “NOTE 7 - Stock Options” for additional information on the Company’s stock-based compensation plans. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively. Segment Reporting The Company’s business is considered to be operating in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations. Net Income (Loss) Per Share The computation of basic earnings per share (“ EPS Following is the computation of basic and diluted net loss per share for the years ended August 31, 2020 and 2019: Years Ended August 31, 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (7,353,062 ) $ (6,887,678 ) Denominator: Weighted average number of common shares outstanding 52,959,323 48,986,720 Basic and diluted EPS $ (0.14 ) $ (0.14 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,804,734 2,777,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,288,251 22,260,851 Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for the Company for fiscal years beginning after August 31, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company’s annual fiscal year. The Company will early adopt ASU 2020-06 beginning with our fiscal year starting on September 1, 2021. We do not expect the adoption of ASU 2020-06 to have a material impact on our consolidated financial statements. In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. The Company adopted ASU 2017-09 beginning September 1, 2018 with no impact on its Financial Statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted ASU No. 2016-02 beginning September 1, 2018. The adoption of the standard did not impact the Company’s consolidated net earnings and had no impact on cash flows. As of May 1, 2019, the Company entered into an operating lease for office space. See “NOTE 8 – Lease” for additional information. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.

Property and Equipment

Property and Equipment	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Property, Plant and Equipment [Abstract]
NOTE 3 - Property and Equipment	NOTE 3 – Property and Equipment Property and equipment consists of the following: November 30, August 31, 2020 2020 Computers, office equipment and software $ 14,800 $ 23,709 Furniture and fixtures 27,726 12,634 Product development and manufacturing equipment 113,820 113,820 In-process equipment 1,292,655 1,292,655 Total property and equipment 1,449,001 1,442,818 Accumulated depreciation (88,498 ) (93,323 ) Property and equipment, net $ 1,360,503 $ 1,349,495 During the three months ended November 30, 2020 and 2019, the company purchased $27,726 and $5,031 of property and equipment, respectively. During the three months ended November 30, 2020 and 2019, the Company recognized depreciation expense of $5,782 and $6,684, respectively. As a result of the closure of the Vestal New York office, during the three months ended November 30, 2020, the Company disposed of office equipment, computers and furniture with an historical cost totaling $21,543 and net book value of 10,936. The Company received $2,161 of proceeds from the sale of the assets resulting in a loss of $8,775.	NOTE 3 – Equipment Equipment consists of the following: August 31, 2020 2019 Computers, office equipment and software $ 23,709 $ 18,678 Furniture and fixtures 12,634 12,634 Product development and manufacturing equipment 113,820 113,820 In-process equipment 1,292,655 1,292,655 Total equipment 1,442,818 1,437,787 Accumulated depreciation (93,323 ) (68,858 ) Equipment, net $ 1,349,495 $ 1,368,929 During the years ended August 31, 2020 and 2019, the Company purchased $5,031 and $1,347,664, respectively, of equipment. During the years ended August 31, 2020 and 2019, the Company recognized depreciation expense of $24,465 and $18,349, respectively. During the year ended August 31, 2019, the Company made payments for in-process equipment totaling $1,292,655 towards the purchase of manufacturing equipment with an estimated total cost of $1,803,000. That in-process equipment will provide a significant increase in our ability to develop and showcase prototype products and components at or near “commercial size.” The remaining $510,345 will be paid upon the completion of the equipment once the final specifications have been determined pending optimization of the Company’s product iteration specific to this equipment.

Debt

Debt	12 Months Ended
	Aug. 31, 2020
Notes to Financial Statements
NOTE 4 - Debt	NOTE 4 - Debt As of August 31, 2018, the Company had the following outstanding debt balances which were converted to Units (defined below) during the year ended August 31, 2019: Issue Date Maturity Date Principal Debt Discount Balance Interest Payable As of August 31, 2018: March 2015 Loan as amended 3/4/2015 12/31/2019 $ 600,000 $ - $ 600,000 $ 186,797 2013 Note as amended 10/7/2013 12/31/2019 3,000,000 (663,918 ) 2,336,082 1,337,146 $ 3,600,000 $ (663,918 ) $ 2,936,082 $ 1,523,943 March 2015 Loan as Amended On March 4, 2015, the Company entered into a Bridge Loan Agreement with 1420468 Alberta Ltd. (which has since been merged with and into Kalen Capital Corporation, a British Columbia corporation wholly-owned by our former Chairman, Harmel S. Rayat (the “ Investor March 2015 Loan On November 3, 2017, the Company entered into the Third Amendment related to the March 2015 Loan pursuant to which the Company and the Investor amended the March 2015 loan to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5%. On November 26, 2018, $798,566 of the March 2015 Loan was converted in exchange for 532,377 Units pursuant to the November 2018 Private Placement except for $7,922 of accrued interest which the Company agreed to repay from proceeds from the November 2018 Private Placement. See “Note 5 – November 2018 Private Placement” for additional information. During the year ended August 31, 2019, the Company recognized $19,691 of interest expense. 2013 Note as Amended On October 7, 2013, the Company sold to the Investor an unsecured Convertible Promissory Note (the “ 2013 Note On November 3, 2017, the Company entered into the Third Amendment related to the 2013 Note pursuant to which the Company and the Investor amended the 2013 Note to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5% and all outstanding warrants held by the Investor had their maturity date extended to December 31, 2022, resulting in an additional debt discount of $1,074,265 as of November 3, 2017. The modification did not result in a gain or loss due to the related party nature of the transaction. During the year ended August 31, 2019, the Company recognized $108,548 of interest expense. Accretion of the debt discount related to the 2013 Note as amended amounted to $663,918 during the year ended August 31, 2019.

November 2018 Private Placement

November 2018 Private Placement	12 Months Ended
	Aug. 31, 2020
Notes to Financial Statements
NOTE 5 - November 2018 Private Placement	NOTE 5 – November 2018 Private Placement On November 26, 2018, the Company completed a self-directed offering (the “ November 2018 Private Placement Unit Series T Warrant The Series T Warrants were accounted for pursuant to ASC 470-20-25-2. The relative fair value of the common stock was estimated to be $13,687,151. The relative fair value of the Series T Warrants was estimated to be $11,312,849 as determined based on the relative fair value allocation of the proceeds received. The Series T Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $2.94 per share; estimated volatility – 85.85%; 7-year risk free interest rate – 2.97%; expected dividend rate - 0% and expected life - 7 years.

Common Stock and Warrants

Common Stock and Warrants	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 6 - Common Stock and Warrants	NOTE 4 – Common Stock and Warrants Common Stock At November 30, 2020, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 52,959,323 shares of common stock outstanding and 5,734,277 shares reserved for issuance under the Company’s 2006 Long-Term Incentive Plan (the “ 2006 Plan Warrants Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. Other than the Series O Warrants and Series P Warrants, all of the following warrants may be exercised on a cashless basis. A summary of the Company’s warrants outstanding and exercisable as of November 30, 2020 and August 31, 2019 is as follows: Shares of Common Stock Weighted Description November 30, August 31, Exercise Date of Expiration 2020 2019 Issuance Series M 246,000 246,000 $ 2.34 December 7, 2015 December 31, 2022 Series N 767,000 767,000 $ 3.38 December 31, 2015 December 31, 2022 Series P 213,500 213,500 $ 3.70 March 25, 2016 December 31, 2022 Series R 468,750 468,750 $ 4.00 June 20, 2016 December 31, 2022 Series S-A 300,000 300,000 $ 2.53 July 24, 2017 December 31, 2022 Series S 821,600 821,600 $ 3.42 September 29, 2017 September 29, 2022 Series T 16,666,667 16,666,667 $ 1.70 November 26, 2018 November 26, 2025 Total 19,483,517 19,483,517	NOTE 6 – Common Stock and Warrants Common Stock At August 31, 2020, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 52,959,323 shares of common stock outstanding and 6,036,685 shares reserved for issuance under the Company’s 2006 Long-Term Incentive Plan (the “ 2006 Plan During the year ended August 31, 2019, the Company completed the November 2018 Private Placement of 16,666,667 units at a price of $1.50 per unit. Each unit consisted of one share of common stock and one Series T Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $1.70 per share for a period of seven (7) years. See “NOTE 5 – November 2018 Private Placement” for additional information. Warrants Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. Other than the Series O Warrants and Series P Warrants, all of the following warrants may be exercised on a cashless basis. A summary of the Company’s warrants outstanding and exercisable as of August 31, 2020 and 2019 is as follows: Shares of Common Stock Issuable from Warrants Weighted Outstanding as of August 31, Average Date Of Description 2020 2019 Exercise Price Issuance Expiration Series M 246,000 246,000 $ 2.34 December 7, 2015 December 31, 2022 Series N 767,000 767,000 $ 3.38 December 31, 2015 December 31, 2022 Series P 213,500 213,500 $ 3.70 March 25, 2016 December 31, 2022 Series R 468,750 468,750 $ 4.00 June 20, 2016 December 31, 2022 Series S-A 300,000 300,000 $ 2.53 July 24, 2017 December 31, 2022 Series S 821,600 821,600 $ 3.42 September 29, 2017 September 29, 2022 Series T 16,666,667 16,666,667 $ 1.70 November 26, 2018 November 26, 2025 Total 19,483,517 19,483,517

Stock Options

Stock Options	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 7 - Stock Options	NOTE 5 - Stock Options Stockholders previously approved 15,000,000 shares for grant under the 2006 Plan. The 2006 Plan was adopted in order to attract and retain the best available personnel for positions of substantial authority and to provide additional incentive to employees and directors to promote the success of the Company’s business. The 2006 Plan provides for the grant of incentive stock options, non-qualified stock options, restricted stock, restricted stock units, stock appreciation rights, and other types of awards to employees, consultants, and directors. Stock option grants pursuant to the 2006 Plan vest either immediately or over zero to five years and expire from six to ten years after the date of grant with the exercise price equal to the fair value of the underlying stock on the date of grant. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised and therefore issues new shares when options are exercised. The 2006 Plan was approved by stockholders on February 7, 2011 and expires according to its terms on February 7, 2021. The Company measures share-based compensation cost on the grant date, based on the fair value of the award, and recognizes the expense on a straight-line basis over the requisite service period for awards expected to vest. The Company estimated the grant date fair value of stock options using a Black-Scholes valuation model using the following weighted-average assumptions: Three Months Ended November 30, 2020 2019 Expected dividend yield – – Expected stock price volatility 89.44 % 82.94 – 86.23% Risk-free interest rate 0.19 % 1.40 – 1.69% Expected term (in years)(simplified method) 4.00 4.5 – 5.75 Exercise price $ 3.42 $2.32 and $3.54 Weighted-average grant date fair-value $ 2.16 $1.61 and $1.55 A summary of the Company’s stock option activity for the three months ended November 30, 2020 and related information follows: Number of Weighted Weighted Aggregate Outstanding at August 31, 2019 2,777,334 4.31 Grants 5,158,000 4.06 Forfeitures and cancellations (130,600 ) 3.54 Outstanding at August 31, 2020 7,804,734 4.16 Grants 50,000 3.42 Forfeitures and cancellations (37,500 ) 3.54 Outstanding at November 30, 2020 7,817,234 4.16 5.29 years 27,557,385 Exercisable at November 30, 2020 3,956,434 3.66 6.30 years 15,789,872 The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on November 30, 2020. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $7.65 on November 30, 2020 and 6,386,567 outstanding options have an exercise price below $7.65 per share, as of November 30, 2020, there is $25,886,685 and $14,070,872 of intrinsic value to the totality of the Company’s outstanding stock options and vested options, respectively. Three Months Ended , 2020 On October 19, the Company’s Board granted 50,000 options to Joseph Sierchio, Director, with an exercise price of $3.42, exercisable on a cashless basis any time prior to the Company’s listing of any of its securities for trading on a national stock exchange, six year term and vesting at the rate of 12,500 on the date of grant and 12,500 each anniversary thereafter. Three Months Ended , 2019 On October 9, 2019, the Company granted 153,000 options to an employee with a ten-year term, exercise price of $2.32 per share and vesting at the rate of 1/36th per month. Additionally, on September 16, 2019, the Board granted 5,000 options with a six-year term to a consultant with an exercise price of $3.54 per share and vesting at the rate of 1/20th per quarter. The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three months ended November 30, 2020 and 2019: Three Months Ended November 30, 2020 2019 Stock Compensation Expense: SG&A $ 1,533,824 $ 172,219 R&D 304,708 248,751 Total $ 1,838,532 $ 420,970 As of November 30, 2020, the Company had $5,297,826 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 3.75 years. The following table summarizes information about stock options outstanding and exercisable at November 30, 2020: Stock Options Outstanding Stock Options Exercisable Range of Number of Shares Weighted Weighted Number Weighted Average Weighted 2.32 153,000 8.86 2.32 55,250 8.86 2.32 2.60 2,500,000 5.59 2.60 1,250,000 5.59 2.60 3.28 7,500 5.96 3.28 7,500 5.96 3.28 3.42 50,000 5.89 3.42 12,500 5.89 3.42 3.46 35,000 5.10 3.46 35,000 5.10 3.46 3.54 1,342,900 7.61 3.54 1,140,350 8.14 3.54 3.66 1,000,000 2.75 3.66 500,000 2.75 3.66 4.87 187,500 6.98 4.87 187,500 6.98 4.87 5.35 1,008,000 7.09 5.35 735,000 7.09 5.35 5.94 33,334 0.06 5.94 33,334 0.06 5.94 6.00 800,000 2.75 6.00 - 2.75 6.00 8.00 700,000 2.75 8.00 - 2.75 8.00 Total 7,817,234 5.29 4.16 3,956,434 6.30 3.66	NOTE 7 - Stock Options Stock option grants pursuant to the 2006 Plan vest either immediately or over zero to five years and expire from six to ten years after the date of grant. Stockholders previously approved 15,000,000 shares for grant under the 2006 Plan, of which 6,036,685 remain available for grant, 1,305,001 have been exercised in total with 629,677 net shares (due to a cashless exercise feature) issued pursuant to such exercises of vested options from inception of the 2006 Plan through August 31, 2020. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised and therefore issues new shares when options are exercised. The 2006 Plan was approved by stockholders on February 7, 2011 and expires according to its terms on February 7, 2021. The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes Model and the simplified method to estimate the expected term of “plain vanilla” options: Years Ended August 31, 2020 2019 Expected dividend yield – – Expected stock price volatility 82.94 – 99.44 % 87.42 – 87.84 % Risk-free interest rate 0.08 – 1.69 % 1.84 % Expected term (in years) 1.87 – 5.75 4.5 – 5.0 Exercise price $ 2.32 – 8.00 $ 3.54 Weighted-average grant date fair-value $ 1.15 – 1.84 $ 2.35 – 2.43 A summary of the Company’s stock option activity for the years ended August 31, 2020 and 2019 and related information follows: Number of Shares Subject to Option Grants Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value ($) Outstanding at August 31, 2018 1,291,334 5.22 Grants 1,506,000 3.54 Forfeitures and cancellations (20,000 ) 4.87 Outstanding at August 31, 2019 2,777,334 4.31 Grants 5,158,000 4.06 Forfeitures and cancellations (130,600 ) 3.54 Outstanding at August 31, 2020 7,804,734 4.16 5.54 3,030,518 Exercisable at August 31, 2020 3,853,734 3.64 6.54 1,526,908 The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on August 31, 2020. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $3.66 on August 30, 2020 and 4,075,900 outstanding options have an exercise price below $3.66 per share, as of August 31, 2020, there is $3,030,518 and $1,526,908 of intrinsic value to the totality of the Company’s outstanding stock options and vested options, respectively. Year Ended August 31, 2020 On August 31, 2020, the Company’s Board granted 2,500,000 options to John Rhee, Director and CEO of our Korean subsidiary with an exercise price of $3.66 as to 1,000,000 options, $6.00 as to 800,000 options and $8.00 as to 700,000 options, exercisable on a cashless basis any time prior to the Company’s listing of any of its securities for trading on a national stock exchange, three year term and vesting at the rate of 500,000 on the date of grant, 800,000 on the six month anniversary, 700,000 on the one-year anniversary and 500,000 on the eighteen month anniversary. On July 1, 2020, the Company’s Board granted 2,500,000 options to Jatinder S. Bhogal with an exercise price of $2.60, exercisable on a cashless basis any time prior to the Company’s listing of any of its securities for trading on a national stock exchange, six year term and immediate vesting as to 1,250,000 options and July 1, 2021 as to 1,250,000 options. On October 9, 2019, the Company granted 153,000 options to an employee with an exercise price of $2.32, vesting at the rate of 1/36 th On September 16, 2019, the Board granted 5,000 options to a consultant with an exercise price of $3.54, vesting at the rate of 1/20 th During the year ended August 31, 2020, there were 130,600 vested options forfeited. Year Ended August 31, 2019 On July 5, 2019, the Company’s Board granted 498,000 options to directors and employees with an exercise price of $3.54, vesting at the rate of 1/20 th Due to his resignation from the Board of Directors on October 22, 2018, Joseph Sierchio forfeited 20,000 unvested stock options with an exercise price of $4.87 which resulted in the Company reversing previously recorded stock compensation expense related to the vesting of said options in the amount of $58,367. The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the years ended August 31, 2020 and 2019: Year Ended August 31, 2020 2019 Stock Compensation Expense: SG&A $ 3,788,538 $ 2,993,532 R&D 1,084,371 965,835 Total $ 4,872,909 $ 3,959,367 As of August 31, 2020, the Company had $7,116,483 of unrecognized compensation cost related to unvested stock options which is expected to be recognized over a period of 4.00 years. The following table summarizes information about stock options outstanding and exercisable at August 31, 2020: Stock Options Outstanding Stock Options Exercisable Range of Number of Shares Weighted Weighted Number Weighted Average Weighted 2.32 153,000 9.11 2.32 42,500 9.11 2.32 2.60 2,500,000 5.84 2.60 1,250,000 5.84 2.60 3.28 7,500 6.21 3.28 7,500 6.21 3.28 3.46 35,000 5.35 3.46 35,000 5.35 3.46 3.54 1,380,400 7.78 3.54 1,125,900 8.43 3.54 3.66 1,000,000 3.00 3.66 500,000 3.00 3.66 4.87 187,500 7.23 4.87 187,500 7.23 4.87 5.35 1,008,000 7.34 5.35 672,000 7.34 5.35 5.94 33,334 0.31 5.94 33,334 0.31 5.94 6.00 800,000 3.00 6.00 - 3.00 6.00 8.00 700,000 3.00 8.00 - 3.00 8.00 Total 7,804,734 5.54 4.16 3,853,734 6.54 3.64

Lease

Lease	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 8 - Lease	NOTE 6 – Lease On May 1, 2019, the Company leased office space in Vestal, New York and entered into a Professional Building Lease Agreement (the “ Lease As of November 30, 2020, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations. The components of Lease expenses are as follows: Three Months Ended November 30, 2020 2020 (a) Operating lease cost $ 32,648 $ 6,666 Short-term lease costs - - Total net lease costs $ 32,648 $ 6,666 (a) Supplemental balance sheet information related to the Lease is as follows: November 30, August 31, 2020 2020 Operating lease right-of-use asset $ - $ 42,212 Current maturities of operating lease $ - $ 24,828 Non-current operating lease - 17,736 Total operating lease liabilities $ - $ 42,564 Weighted Average remaining lease term (in years): - 1.67 Discount rate: - 5.85 % In September 2020, the Company, through its wholly owned subsidiaries, SolarWindow Asia (USA) Corp. and SolarWindow Asia Co., Ltd., entered a lease for office space in South Korea. The lease has a term of one year from September 23, 2020 through September 23, 2021 with monthly payments of approximately $1,200.	NOTE 8 – Lease On May 1, 2019, the Company leased office space in Vestal, New York and entered into a Professional Building Lease Agreement (the “ Lease The Company’s existing Lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s. As of August 31, 2020, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations. The Company used its estimated incremental borrowing rate as the basis to calculate the present value of future lease payments at lease commencement. The incremental borrowing rate represents the rate the Company would have to pay to borrow funds on a collateralized basis over a similar term and in a similar economic environment. The components of Lease expenses are as follows: Year Ended August 31, 2020 2020 2019 Operating lease cost $ 26,664 $ 8,888 Short-term lease costs - - Total net lease costs $ 26,664 $ 8,888 supplemental balance sheet information related to the Lease is as follows: As of August 31, 2020 2019 Operating lease right-of-use asset $ 42,212 $ 65,646 Current maturities of operating lease $ 24,828 $ 23,169 Non-current operating lease 17,736 42,564 Total operating lease liabilities $ 42,564 $ 65,733 Weighted Average remaining lease term (in years): 1.67 2.9 Discount rate: In September 2020, the Company, through its wholly owned subsidiaries, SolarWindow Asia (USA) Corp. and SolarWindow Asia Co., Ltd., entered a lease for office space in South Korea. The lease has a term of one year from September 23, 2020 through September 23, 2021 with monthly payments of approximately $1,200. The Company’s future lease payments, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s balance sheets as of August 31, 2020 are as follows: Amount 2021 26,664 2022 18,128 Total lease payments 44,792 Less: Imputed interest (2,228 ) Total lease obligation 42,564 Less: current lease obligations 24,828 Long term lease obligations $ 17,736

Transactions with Related Perso

Transactions with Related Persons	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 9 - Transactions with Related Persons	NOTE 7 - Transactions with Related Persons A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company’s securities, (ii) that is part of the Company’s management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. On August 7, 2017, the Company appointed Jatinder Bhogal to the Board of Directors. Mr. Bhogal has provided consulting services to the Company through his wholly owned company, Vector Asset Management, Inc., pursuant to a Consulting Agreement dated February 1, 2014, as amended on November 11, 2016 and December 1, 2018 (Amendment No. 2). On July 1, 2020 the Company and VAMI entered into an Executive Consulting Agreement, which supersedes the foregoing agreements and pursuant to which Mr. Bhogal, in addition to continuing to serve as a director of the Company will also serve as the Company’s President and Chief Executive Officer. Pursuant to the Consulting Agreements in effect prior to December 1, 2018, Mr. Bhogal received compensation of $5,000 per month. Beginning with Amendment No. 2, Mr. Bhogal received compensation of $18,750 per month and pursuant to the ECA, Mr. Bhogal receives $34,167 per month. Mr. Bhogal also incurs expenses on behalf of the Company which are reimbursed according to the Company’s expense report policy. The Company recognized cash compensation expense in connection with the Consulting Agreements and ECA of $102,500 and $56,250 during the three months ended November 30, 2020 and 2019, respectively. As of November 30, 2020, the Company recognized a related party payable to Mr. Bhogal of $34,167. During the three months ended November 30, 2020 and 2019, the Company received advances of $0 and $73,005, respectively, from Talia Jevan Properties, Inc., a British Columbia corporation wholly-owned by our former Chairman and majority stockholder, Harmel S. Rayat. The Company repaid Talia Jevan Properties $53,251 and $0 during the three months ended November 30, 2020 and 2019. As of November 30, 2020, there were no balances owing to Talia Jevan Properties, Inc. Joseph Sierchio, one of the Company’s directors, has maintained his role as the Company’s General Counsel since its inception as Principal of the law firm of Sierchio & Partners, LLP, and then as a Partner with Satterlee Stephens LLP and beginning in August 2020, as Principal of Sierchio Law, LLP pursuant to an engagement letter which provides for an annual fee of $175,000 in exchange for general counsel services. Mr. Sierchio resigned from the Board effective October 22, 2018, and was reappointed on October 1, 2020. During the three months ended November 30, 2020 and 2019, the Company recognized $43,750 and $43,750 of fees for legal services billed by Sierchio Law, LLP. All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.	NOTE 9 - Transactions with Related Persons A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company’s securities, (ii) that is part of the Company’s management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. On August 7, 2017, the Company appointed Jatinder Bhogal to the Board of Directors. Mr. Bhogal has provided consulting services to the Company through his wholly owned company, Vector Asset Management, Inc., pursuant to a Consulting Agreement dated February 1, 2014, as amended on November 11, 2016 and December 1, 2018 (Amendment No. 2). On July 1, 2020 the Company and VAMI entered into an Executive Consulting Agreement, which supersedes the foregoing agreements and pursuant to which Mr. Bhogal, in addition to continuing to serve as a director of the Company will also serve as the Company’s President and Chief Executive Officer. Pursuant to the Consulting Agreements in effect prior to December 1, 2018, Mr. Bhogal received compensation of $5,000 per month. Beginning with Amendment No. 2, Mr. Bhogal received compensation of $18,750 per month and pursuant to the ECA, Mr. Bhogal receives 34,167 per month. Mr. Bhogal also incurs expenses on behalf of the Company which are reimbursed according to the Company’s expense report policy. The Company recognized cash compensation expense in connection with the Consulting Agreements and ECA of $255,833 and $183,750 during the years ended August 31, 2020 and 2019, respectively. As of August 31, 2020, the Company recognized a related party payable to Mr. Bhogal of $48,758. During the year ended August 31, 2020, Talia Jevan Properties, Inc., a British Columbia corporation wholly-owned by the Investor, made advances on behalf of the Company totaling $210,415 and $15,497 during the years ended August 31, 2020 and 2019, respectively. The Company repaid Talia Jevan Properties $172,661 and $0 during the years ended August 31, 2020 and 2019, respectively. As of August 31, 2020, the Company owed Talia Jevan Properties, Inc. $53,251. The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Company’s directors, was a principal, had provided counsel to the Company since its inception. Beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (“Satterlee”). Concurrently with Mr. Sierchio’s move to Satterlee, the Company engaged with Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Company’s primary attorney. Mr. Sierchio resigned from the Board effective October 22, 2018, and was reappointed on October 1, 2020. Mr. Sierchio has maintained his role as the Company’s General Counsel. During our fiscal year ended August 31, 2019 (from September 1, 2018 through October 22, 2018, the date of Mr. Sierchio’s resignation from the Board), the Company recognized $3,480 of fees for legal services billed by firms associated with Mr. Sierchio. On November 26, 2018, the Company completed the November 2018 Private Placement to accredited investors of 16,666,667 Units of the Company’s equity securities at a price of $1.50 per Unit with each Unit comprised of (a) one share of common stock; and (b) one Series T Warrant to purchase one share of common stock at a price of $1.70 per share for a period of seven (7) years. The Investor participated in the November 2018 Private Placement by purchasing 13,100,000 Units in exchange for cash of $19,650,000 and converting $5,200,000 owing under the March 2015 Loan and 2013 Note into 3,466,667 Units. All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

Income Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2020
Notes to Financial Statements
NOTE 10 - Income Taxes	NOTE 10 – Income Taxes On December 22, 2017, the Tax Cuts and Jobs Act (“The Act”) was enacted into law. The Act applies to corporations generally beginning with taxable years starting after December 31, 2017 and reduces the corporate tax rate from a graduated set of rates with a maximum 35% tax rate to a flat 21% tax rate. Additionally, the Act introduced other changes that impacted corporations, including a net operating loss (“NOL”) deduction annual limitation, an interest expense deduction annual limitation, elimination of the alternative minimum tax, and immediate expensing of the full cost of qualified property. The Act also introduced an international tax reform that moved the U.S. toward a territorial system, in which income earned in other countries will generally not be subject to U.S. taxation. However, the accumulated foreign earnings of certain foreign corporations were subject to a one-time transition tax, which can be elected to be paid over an eight-year tax transition period, using specified percentages, or in one lump sum. NOL and foreign tax credit (“FTC”) carryforwards can be used to offset the transition tax liability. This change had no impact on the Company as it has not earned taxable income in the past and it has significant NOL carryforwards. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets at August 31, 2020 and 2019 are as follows: 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 6,598,870 $ 5,901,666 Capitalized research and development 1,069,124 1,014,380 Depreciation 1,762 (7,353 ) Stock based compensation 3,006,736 1,983,425 Research and development credit carry forward 657,737 599,646 Total deferred tax assets 11,334,229 9,491,764 Less: valuation allowance (11,334,229 ) (9,491,764 ) Net deferred tax asset $ - $ - The net increase in the valuation allowance for deferred tax assets was $1,842,465 and $1,594,583 during the year ended August 31, 2020 and 2019, respectively. The Company evaluates its valuation allowance requirements on an annual basis based on projected future operations. When circumstances change and this causes a change in management’s judgment about the realizability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current operations. For federal income tax purposes, the Company has net U.S. operating loss carry forwards at August 31, 2020 available to offset future federal taxable income, if any, of $31,423,193. These carryforwards may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. In addition, the Company has research and development tax credit carry forwards of $657,737 at August 31, 2020, which are available to offset federal income taxes. The utilization of the tax net operating loss carry forwards may be limited due to ownership changes that have occurred as a result of sales of common stock. The effects of state income taxes were insignificant for the years ended August 31, 2020 and 2019. The following is a reconciliation between expected income tax benefit and actual, using the applicable statutory income tax rate of 21% for the year ended August 31, 2020 and 2019: 2020 2019 Income tax benefit at statutory rate $ 1,544,143 $ 1,446,412 Permanent differences 240,231 69,190 Research and development credit 58,091 78,981 Change in valuation allowance (1,842,465 ) (1,594,583 ) $ - $ - The fiscal years 2018 through 2020 remain open to examination by federal authorities and other jurisdictions in which the Company operates. The Company does not have any uncertain tax positions at August 31, 2020 and 2019 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties as part of income tax expense.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
NOTE 11 - Commitments and Contingencies	NOTE 8 – Commitments and Contingencies In September 2020, the Company, through its wholly owned subsidiaries, SolarWindow Asia (USA) Corp. and SolarWindow Asia Co., Ltd., entered a lease for office space in South Korea. The lease has a term of one year from September 23, 2020 through September 23, 2021 with monthly payments of approximately $1,200. During 2019 the Company made payments totaling $1,292,655 towards the purchase of manufacturing equipment with an estimated total cost of $1,803,000. The remaining $510,345 will be paid upon the completion of the equipment once the final specifications have been determined pending optimization of the Company’s product iteration specific to this equipment. For additional information, see “Note 3 – Property and Equipment” located in the footnotes to our financial statements. COVID-19 In December 2019, an outbreak of the COVID-19 virus was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared the COVID-19 virus a global pandemic and on March 13, 2020, President Donald J. Trump declared the virus a national emergency in the United States. This highly contagious disease has spread to most of the countries in the world and throughout the United States, creating a serious impact on customers, workforces and suppliers, disrupting economies and financial markets, and potentially leading to a world-wide economic downturn. It has caused a disruption of the normal operations of many businesses, including the temporary closure or scale-back of business operations and/or the imposition of either quarantine or remote work or meeting requirements for employees, either by government order or on a voluntary basis. The pandemic may adversely affect our operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. Our employees are working remotely and using various technologies to perform their functions. In reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. The disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.	NOTE 11 – Commitments and Contingencies The Company entered into an operating lease for office space with a term from May 1, 2019 through May 1, 2022 with monthly rent due of $2,200 for the first two years and $2,266 during year three. For additional information, see “Note 8 – Lease” located in the footnotes to our financial statements. In September 2020, the Company, through its wholly owned subsidiaries, SolarWindow Asia (USA) Corp. and SolarWindow Asia Co., Ltd., entered a lease for office space in South Korea. The lease has a term of one year from September 23, 2020 through September 23, 2021 with monthly payments of approximately $1,200. During 2019 the Company made payments totaling $1,292,655 towards the purchase of manufacturing equipment with an estimated total cost of $1,803,000. The remaining $510,345 will be paid upon the completion of the equipment once the final specifications have been determined pending optimization of the Company’s product iteration specific to this equipment. For additional information, see “Note 3 – Equipment” located in the footnotes to our financial statements. COVID-19 In December 2019, an outbreak of the COVID-19 virus was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared the COVID-19 virus a global pandemic and on March 13, 2020, President Donald J. Trump declared the virus a national emergency in the United States. This highly contagious disease has spread to most of the countries in the world and throughout the United States, creating a serious impact on customers, workforces and suppliers, disrupting economies and financial markets, and potentially leading to a world-wide economic downturn. It has caused a disruption of the normal operations of many businesses, including the temporary closure or scale-back of business operations and/or the imposition of either quarantine or remote work or meeting requirements for employees, either by government order or on a voluntary basis. The pandemic may adversely affect our operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. Our employees are working remotely and using various technologies to perform their functions. In reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. The disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Nov. 30, 2020
Earnings Per Share [Abstract]
NOTE 9 - Net Income (Loss) Per Share	NOTE 9 - Net Income (Loss) Per Share The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money). Following is the computation of basic and diluted net loss per share for the three months ended November 30, 2020 and 2019: Three Months Ended 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (2,537,035 ) $ (1,105,278 ) Denominator: Weighted average number of common shares outstanding 52,959,323 52,959,323 Basic and diluted EPS $ (0.05 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,817,234 2,935,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,300,751 22,418,851

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Subsequent Events [Abstract]
NOTE 12 - Subsequent Events	NOTE 10 – Subsequent Events Management has reviewed material events subsequent of the period ended November 30, 2020 and through the date of filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. In managements opinion, no material subsequent events have occurred as of the date of this quarterly report. On December 18, 2020, one of our Directors exercised 16,667 stock options on a cashless basis resulting in the issuance of 5,667 shares of restricted common stock. On December 18, 2020, Mr. John Conklin and the Company entered into an Amendment to the Separation, Consulting and Release of Claims Agreement dated November 24, 2020. Pursuant to the Amendment, no further payments are due to Mr. Conklin and all stock options granted under his employment agreement totaling 1,008,000 are cancelled.	NOTE 12 – Subsequent Events Management has reviewed material events subsequent of the period ended August 31, 2020 and through the date of filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. In managements opinion, no material subsequent events have occurred as of the date of this annual report. From September 1 – October 26, 2020, the Company made capital contributions of $78,000 to SolarWindow Asia Co., Ltd., a Korean foreign direct investment company. The Board has approved an additional $753,000 for transfer to the Korean subsidiary. On October 20, 2020, the Company settled all outstanding related party payables to Talia Jevan Properties, Inc., by making a payment of $53,251. On October 19, 2020, the Company granted 50,000 options to Joseph Sierchio in connection with his appointment to the Board. The options have an exercise price of $3.42, vest as to 12,500 immediately and 12,500 each anniversary thereafter and expires on October 19, 2026.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Summary Of Significant Accounting Policies
Fiscal quarter	Fiscal quarter The Company’s quarterly periods end on November 30, February 28, May 31, and August 31. The Company’s first quarter in fiscal 2021 and 2020 ended on November 30, 2020 and 2019, respectively.
Principles of Consolidation	Principles of consolidation On August 24, 2020, the Company formed wholly owned SolarWindow Asia (USA) Corp. as the holding company for SolarWindow Asia Co. Ltd., a company formed in the Republic of Korea for the purpose of expansion into the Asian markets. As of August 31, 2020, the Company had not capitalized the Korean subsidiaries and there were no transactions related to these entities during the year ended August 31, 2020. During our fiscal quarter ended November 30, 2020, the Company capitalized SolarWindow Asia Co. Ltd. with a transfer of $831,000. These consolidated financial statements presented are those of SolarWindow Technologies, Inc. and its wholly owned subsidiaries, SolarWindow Asia (USA) Corp., and SolarWindow Asia Co. Ltd. All significant intercompany balances and transactions have been eliminated.	Principles of Consolidation On July 5, 2019, the Board of Directors voted to dissolve Kinetic Energy Corporation (“KEC”) and New Energy Solar (“NES”). KEC was incorporated on June 19, 2008. NES was incorporated on February 9, 2009. Neither KEC nor NES had operating activity for the year ended August 31, 2019. On August 24, 2020, the Company formed wholly owned SolarWindow Asia (USA) Corp. as the holding company for SolarWindow Asia Co. Ltd., a company formed in the Republic of Korea for the purpose of expansion into the Asian markets. As of August 31, 2020, the Company had not capitalized the Korean subsidiaries and there were no transactions related to these entities during the year ended August 31, 2020. As a result, the financial statements presented are solely those of SolarWindow Technologies, Inc.
Use of Estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the accounting period. The Company considers its accounting policies relating to stock based compensation to be the most significant accounting policy that involves management estimates and judgments. The Company has made accounting estimates based on the facts and circumstances available as of the reporting date. Actual amounts could differ from these estimates, and such differences could be material.	Use of Estimates The preparation of the Company’s financial statements requires management to make estimates and use assumptions that affect the reported amounts of assets, liabilities and expenses. These estimates and assumptions are affected by management’s application of accounting policies. On an on-going basis, the Company evaluates its estimates. Actual results and outcomes may differ materially from these estimates and assumptions.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and highly liquid investments with original maturities of three months or less from the date of purchase. November 30, 2020 August 31, 2020 Cash and cash equivalents $ 8,549,510 $ 14,151,523 Short-term investment 5,000,000 - Cash and cash equivalents $ 13,549,510 $ 14,151,523	Cash and Cash Equivalents The Company considers cash deposits to be cash and all highly liquid investment instruments with original maturities of 90 days or less when purchased, to be cash equivalents. Cash deposits are carried at cost which approximates their fair value. The Company had $14,151,523 of cash deposits as of August 31, 2020, including $282,042 in domestic bank accounts and $13,869,481 held in Canadian bank accounts in excess of Canadian Deposit Insurance Corporation insured limits.
Leases		Leases The Company recognizes their leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating lease for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
Equipment		Equipment Fixed assets are carried at cost, less accumulated depreciation. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in that period. Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives (in years) Computer equipment and software 3 Equipment, furniture and fixtures 5
Patent and Trademark Costs		Patent and Trademark Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Fair Value Measurements		Fair Value Measurements The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 1 inputs. Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 2 inputs. Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 3 inputs.
Fair Value of Financial Instruments		Fair Value of Financial Instruments The carrying value of cash and accounts payable approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.
Research and Product Development		Research and Product Development Research and product development costs represent costs incurred to develop the Company’s technology, including salaries and benefits for research and development personnel, allocated overhead and facility occupancy costs, supplies, equipment purchase and repair and other costs. Research and product development costs are expensed when incurred, except for nonrefundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed.
Stock-Based Compensation		Stock-Based Compensation The Company accounts for stock-based compensation in accordance with Accounting Standards Codification (“ASC”) 718, Stock Based Compensation. ASC 718 requires all stock-based payments to directors, employees and consultants, including grants of stock options, to be recognized in the consolidated statements of operations based on their fair values. The Company uses the Black-Scholes option pricing model (the “ Black-Scholes Model The determination of the fair value of stock-based payment awards utilizing the Black-Scholes option pricing model requires the use of the following assumptions: expected volatility of our common stock, which is based on our own calculated historical rate; expected life of the option award, which we elected to calculate using the simplified method; expected dividend yield, which is 0%, as we have not paid and do not have any plans to pay dividends on our common stock; and the risk-free interest rate, which is based on the U.S. Treasury rate in effect at the time of grant with maturities equal to the stock option award’s expected life. The Company evaluates the assumptions used to value the awards at each grant date and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. Forfeitures are accounted for as they occur. See “NOTE 6 – Common Stock and Warrants” and “NOTE 7 - Stock Options” for additional information on the Company’s stock-based compensation plans.
Income Taxes		Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.
Segment Reporting		Segment Reporting The Company’s business is considered to be operating in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations.
Net Income (Loss) Per Share		Net Income (Loss) Per Share The computation of basic earnings per share (“ EPS Following is the computation of basic and diluted net loss per share for the years ended August 31, 2020 and 2019: Years Ended August 31, 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (7,353,062 ) $ (6,887,678 ) Denominator: Weighted average number of common shares outstanding 52,959,323 48,986,720 Basic and diluted EPS $ (0.14 ) $ (0.14 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,804,734 2,777,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,288,251 22,260,851
Short-term investments	Short-term investments The Company determines the balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. Money market funds, certificates of deposit, and time deposits with maturities of greater than three months but no more than twelve months are carried at cost, which approximates fair value and are recorded in the consolidated balance sheets in short-term investments. As of November 30, 2020, the short-term investment consists of a fixed-term deposit with a twelve month maturity at the time of purchase on October 1, 2020.
Recent accounting pronouncements not yet adopted	Recent accounting pronouncements not yet adopted In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial position, results of operations, or cash flows.
Recent Accounting Standards	Recently adopted accounting pronouncements The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the consolidated financial statements.	Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for the Company for fiscal years beginning after August 31, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company’s annual fiscal year. The Company will early adopt ASU 2020-06 beginning with our fiscal year starting on September 1, 2021. We do not expect the adoption of ASU 2020-06 to have a material impact on our consolidated financial statements. In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. The Company adopted ASU 2017-09 beginning September 1, 2018 with no impact on its Financial Statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company early adopted ASU No. 2016-02 beginning September 1, 2018. The adoption of the standard did not impact the Company’s consolidated net earnings and had no impact on cash flows. As of May 1, 2019, the Company entered into an operating lease for office space. See “NOTE 8 – Lease” for additional information. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Summary Of Significant Accounting Policies Tables Abstract
Estimated useful lives		Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives (in years) Computer equipment and software 3 Equipment, furniture and fixtures 5
Computation of basic and diluted net loss per share	Following is the computation of basic and diluted net loss per share for the three months ended November 30, 2020 and 2019: Three Months Ended 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (2,537,035 ) $ (1,105,278 ) Denominator: Weighted average number of common shares outstanding 52,959,323 52,959,323 Basic and diluted EPS $ (0.05 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,817,234 2,935,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,300,751 22,418,851	Following is the computation of basic and diluted net loss per share for the years ended August 31, 2020 and 2019: Years Ended August 31, 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (7,353,062 ) $ (6,887,678 ) Denominator: Weighted average number of common shares outstanding 52,959,323 48,986,720 Basic and diluted EPS $ (0.14 ) $ (0.14 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,804,734 2,777,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,288,251 22,260,851
Schedule of Cash and Cash Equivalents	Cash and cash equivalents include cash on hand and highly liquid investments with original maturities of three months or less from the date of purchase. November 30, 2020 August 31, 2020 Cash and cash equivalents $ 8,549,510 $ 14,151,523 Short-term investment 5,000,000 - Cash and cash equivalents $ 13,549,510 $ 14,151,523

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following: November 30, August 31, 2020 2020 Computers, office equipment and software $ 14,800 $ 23,709 Furniture and fixtures 27,726 12,634 Product development and manufacturing equipment 113,820 113,820 In-process equipment 1,292,655 1,292,655 Total property and equipment 1,449,001 1,442,818 Accumulated depreciation (88,498 ) (93,323 ) Property and equipment, net $ 1,360,503 $ 1,349,495	Equipment consists of the following: August 31, 2020 2019 Computers, office equipment and software $ 23,709 $ 18,678 Furniture and fixtures 12,634 12,634 Product development and manufacturing equipment 113,820 113,820 In-process equipment 1,292,655 1,292,655 Total equipment 1,442,818 1,437,787 Accumulated depreciation (93,323 ) (68,858 ) Equipment, net $ 1,349,495 $ 1,368,929

Debt (Tables)

Debt (Tables)	12 Months Ended
	Aug. 31, 2020
Debt
Schedule of debt outstanding	As of August 31, 2018, the Company had the following outstanding debt balances which were converted to Units (defined below) during the year ended August 31, 2019: Issue Date Maturity Date Principal Debt Discount Balance Interest Payable As of August 31, 2018: March 2015 Loan as amended 3/4/2015 12/31/2019 $ 600,000 $ - $ 600,000 $ 186,797 2013 Note as amended 10/7/2013 12/31/2019 3,000,000 (663,918 ) 2,336,082 1,337,146 $ 3,600,000 $ (663,918 ) $ 2,936,082 $ 1,523,943

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Common Stock And Warrants Tables
Warrants outstanding and exercisable	A summary of the Company’s warrants outstanding and exercisable as of November 30, 2020 and August 31, 2019 is as follows: Shares of Common Stock Weighted Description November 30, August 31, Exercise Date of Expiration 2020 2019 Issuance Series M 246,000 246,000 $ 2.34 December 7, 2015 December 31, 2022 Series N 767,000 767,000 $ 3.38 December 31, 2015 December 31, 2022 Series P 213,500 213,500 $ 3.70 March 25, 2016 December 31, 2022 Series R 468,750 468,750 $ 4.00 June 20, 2016 December 31, 2022 Series S-A 300,000 300,000 $ 2.53 July 24, 2017 December 31, 2022 Series S 821,600 821,600 $ 3.42 September 29, 2017 September 29, 2022 Series T 16,666,667 16,666,667 $ 1.70 November 26, 2018 November 26, 2025 Total 19,483,517 19,483,517	A summary of the Company’s warrants outstanding and exercisable as of August 31, 2020 and 2019 is as follows: Shares of Common Stock Issuable from Warrants Weighted Outstanding as of August 31, Average Date Of Description 2020 2019 Exercise Price Issuance Expiration Series M 246,000 246,000 $ 2.34 December 7, 2015 December 31, 2022 Series N 767,000 767,000 $ 3.38 December 31, 2015 December 31, 2022 Series P 213,500 213,500 $ 3.70 March 25, 2016 December 31, 2022 Series R 468,750 468,750 $ 4.00 June 20, 2016 December 31, 2022 Series S-A 300,000 300,000 $ 2.53 July 24, 2017 December 31, 2022 Series S 821,600 821,600 $ 3.42 September 29, 2017 September 29, 2022 Series T 16,666,667 16,666,667 $ 1.70 November 26, 2018 November 26, 2025 Total 19,483,517 19,483,517

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Stock Options Tables
Assumptions	The Company estimated the grant date fair value of stock options using a Black-Scholes valuation model using the following weighted-average assumptions: Three Months Ended November 30, 2020 2019 Expected dividend yield – – Expected stock price volatility 89.44 % 82.94 – 86.23% Risk-free interest rate 0.19 % 1.40 – 1.69% Expected term (in years)(simplified method) 4.00 4.5 – 5.75 Exercise price $ 3.42 $2.32 and $3.54 Weighted-average grant date fair-value $ 2.16 $1.61 and $1.55	The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes Model and the simplified method to estimate the expected term of “plain vanilla” options: Years Ended August 31, 2020 2019 Expected dividend yield – – Expected stock price volatility 82.94 – 99.44 % 87.42 – 87.84 % Risk-free interest rate 0.08 – 1.69 % 1.84 % Expected term (in years) 1.87 – 5.75 4.5 – 5.0 Exercise price $ 2.32 – 8.00 $ 3.54 Weighted-average grant date fair-value $ 1.15 – 1.84 $ 2.35 – 2.43
Stock option activity	A summary of the Company’s stock option activity for the three months ended November 30, 2020 and related information follows: Number of Weighted Weighted Aggregate Outstanding at August 31, 2019 2,777,334 4.31 Grants 5,158,000 4.06 Forfeitures and cancellations (130,600 ) 3.54 Outstanding at August 31, 2020 7,804,734 4.16 Grants 50,000 3.42 Forfeitures and cancellations (37,500 ) 3.54 Outstanding at November 30, 2020 7,817,234 4.16 5.29 years 27,557,385 Exercisable at November 30, 2020 3,956,434 3.66 6.30 years 15,789,872	A summary of the Company’s stock option activity for the years ended August 31, 2020 and 2019 and related information follows: Number of Shares Subject to Option Grants Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value ($) Outstanding at August 31, 2018 1,291,334 5.22 Grants 1,506,000 3.54 Forfeitures and cancellations (20,000 ) 4.87 Outstanding at August 31, 2019 2,777,334 4.31 Grants 5,158,000 4.06 Forfeitures and cancellations (130,600 ) 3.54 Outstanding at August 31, 2020 7,804,734 4.16 5.54 3,030,518 Exercisable at August 31, 2020 3,853,734 3.64 6.54 1,526,908
Share-based compensation cost	The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three months ended November 30, 2020 and 2019: Three Months Ended November 30, 2020 2019 Stock Compensation Expense: SG&A $ 1,533,824 $ 172,219 R&D 304,708 248,751 Total $ 1,838,532 $ 420,970	The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the years ended August 31, 2020 and 2019: Year Ended August 31, 2020 2019 Stock Compensation Expense: SG&A $ 3,788,538 $ 2,993,532 R&D 1,084,371 965,835 Total $ 4,872,909 $ 3,959,367
Stock options outstanding and exercisable	The following table summarizes information about stock options outstanding and exercisable at November 30, 2020: Stock Options Outstanding Stock Options Exercisable Range of Number of Shares Weighted Weighted Number Weighted Average Weighted 2.32 153,000 8.86 2.32 55,250 8.86 2.32 2.60 2,500,000 5.59 2.60 1,250,000 5.59 2.60 3.28 7,500 5.96 3.28 7,500 5.96 3.28 3.42 50,000 5.89 3.42 12,500 5.89 3.42 3.46 35,000 5.10 3.46 35,000 5.10 3.46 3.54 1,342,900 7.61 3.54 1,140,350 8.14 3.54 3.66 1,000,000 2.75 3.66 500,000 2.75 3.66 4.87 187,500 6.98 4.87 187,500 6.98 4.87 5.35 1,008,000 7.09 5.35 735,000 7.09 5.35 5.94 33,334 0.06 5.94 33,334 0.06 5.94 6.00 800,000 2.75 6.00 - 2.75 6.00 8.00 700,000 2.75 8.00 - 2.75 8.00 Total 7,817,234 5.29 4.16 3,956,434 6.30 3.66	The following table summarizes information about stock options outstanding and exercisable at August 31, 2020: Stock Options Outstanding Stock Options Exercisable Range of Number of Shares Weighted Weighted Number Weighted Average Weighted 2.32 153,000 9.11 2.32 42,500 9.11 2.32 2.60 2,500,000 5.84 2.60 1,250,000 5.84 2.60 3.28 7,500 6.21 3.28 7,500 6.21 3.28 3.46 35,000 5.35 3.46 35,000 5.35 3.46 3.54 1,380,400 7.78 3.54 1,125,900 8.43 3.54 3.66 1,000,000 3.00 3.66 500,000 3.00 3.66 4.87 187,500 7.23 4.87 187,500 7.23 4.87 5.35 1,008,000 7.34 5.35 672,000 7.34 5.35 5.94 33,334 0.31 5.94 33,334 0.31 5.94 6.00 800,000 3.00 6.00 - 3.00 6.00 8.00 700,000 3.00 8.00 - 3.00 8.00 Total 7,804,734 5.54 4.16 3,853,734 6.54 3.64

Lease (Tables)

Lease (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Notes to Financial Statements
Components of lease expenses	The components of Lease expenses are as follows: Three Months Ended November 30, 2020 2020 (a) Operating lease cost $ 32,648 $ 6,666 Short-term lease costs - - Total net lease costs $ 32,648 $ 6,666 (a)	The components of Lease expenses are as follows: Year Ended August 31, 2020 2020 2019 Operating lease cost $ 26,664 $ 8,888 Short-term lease costs - - Total net lease costs $ 26,664 $ 8,888
Supplemental balance sheet information related to Lease	Supplemental balance sheet information related to the Lease is as follows: November 30, August 31, 2020 2020 Operating lease right-of-use asset $ - $ 42,212 Current maturities of operating lease $ - $ 24,828 Non-current operating lease - 17,736 Total operating lease liabilities $ - $ 42,564 Weighted Average remaining lease term (in years): - 1.67 Discount rate: - 5.85 %	Supplemental balance sheet information related to the Lease is as follows: As of August 31, 2020 2019 Operating lease right-of-use asset $ 42,212 $ 65,646 Current maturities of operating lease $ 24,828 $ 23,169 Non-current operating lease 17,736 42,564 Total operating lease liabilities $ 42,564 $ 65,733 Weighted Average remaining lease term (in years): 1.67 2.9 Discount rate:
Schedule of future lease payments		The Company’s future lease payments, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s balance sheets as of August 31, 2020 are as follows: Amount 2021 26,664 2022 18,128 Total lease payments 44,792 Less: Imputed interest (2,228 ) Total lease obligation 42,564 Less: current lease obligations 24,828 Long term lease obligations $ 17,736

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2020
Notes to Financial Statements
Deferred income taxes	Significant components of the Company’s deferred tax assets at August 31, 2020 and 2019 are as follows: 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 6,598,870 $ 5,901,666 Capitalized research and development 1,069,124 1,014,380 Depreciation 1,762 (7,353 ) Stock based compensation 3,006,736 1,983,425 Research and development credit carry forward 657,737 599,646 Total deferred tax assets 11,334,229 9,491,764 Less: valuation allowance (11,334,229 ) (9,491,764 ) Net deferred tax asset $ - $ -
Schedule of effective income tax rate reconciliation	The following is a reconciliation between expected income tax benefit and actual, using the applicable statutory income tax rate of 21% for the year ended August 31, 2020 and 2019: 2020 2019 Income tax benefit at statutory rate $ 1,544,143 $ 1,446,412 Permanent differences 240,231 69,190 Research and development credit 58,091 78,981 Change in valuation allowance (1,842,465 ) (1,594,583 ) $ - $ -

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Earnings Per Share [Abstract]
Schedule of Net Income (Loss) Per Share (Tables)	Following is the computation of basic and diluted net loss per share for the three months ended November 30, 2020 and 2019: Three Months Ended 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (2,537,035 ) $ (1,105,278 ) Denominator: Weighted average number of common shares outstanding 52,959,323 52,959,323 Basic and diluted EPS $ (0.05 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,817,234 2,935,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,300,751 22,418,851	Following is the computation of basic and diluted net loss per share for the years ended August 31, 2020 and 2019: Years Ended August 31, 2020 2019 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (7,353,062 ) $ (6,887,678 ) Denominator: Weighted average number of common shares outstanding 52,959,323 48,986,720 Basic and diluted EPS $ (0.14 ) $ (0.14 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 7,804,734 2,777,334 Warrants 19,483,517 19,483,517 Total shares not included in the computation of diluted losses per share 27,288,251 22,260,851

Organization (Details Narrative

Organization (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2020	Aug. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Aug. 31, 2018
Basis Of Presentation Organization And Going Concern Details Narrative Abstract
State of incorporation	NV
Date of incorporation	May 5, 1998
Cash	$ 8,549,510	$ 14,151,523	$ 15,950,512	$ 16,604,011	$ 696,826
Working capital	13,897,863	14,590,959
Cash and cash equivalents and short term investments on hand	$ 13,549,510	$ 14,151,523

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Aug. 31, 2020
Computers, office equipment and software [Member]
Estimated useful lives	3 years
Furniture and Fixtures [Member]
Estimated useful lives	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Numerator:
Loss available to common stockholders'	$ (2,537,035)	$ (1,105,278)	$ (7,353,062)	$ (6,887,678)
Denominator:
Weighted average number of common shares outstanding	52,959,323	52,959,323	52,959,323	48,686,720
Basic and diluted EPS	$ (0.05)	$ (0.02)	$ (0.14)	$ (0.14)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options	7,817,234	2,935,334	7,804,734	2,777,334
Warrants	19,483,517	19,483,517	19,483,517	19,483,517
Total shares not included in the computation of diluted losses per share	27,300,751	22,418,851	27,288,251	22,260,851

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Aug. 31, 2018
Summary Of Significant Accounting Policies Details Abstract
Cash and cash equivalents	$ 8,549,510	$ 14,151,523	$ 15,950,512	$ 16,604,011	$ 696,826
Short-term investment	5,000,000
Cash and cash equivalents	$ 13,549,510	$ 14,151,523

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2020	Aug. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Aug. 31, 2018
Cash	$ 8,549,510	$ 14,151,523	$ 15,950,512	$ 16,604,011	$ 696,826
Domestic bank accounts		282,042
FDIC insured limits		$ 13,869,481
Solar Window Asia [Member]
Consideration Transferred	$ 831,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Total equipment	$ 1,449,001	$ 1,442,818	$ 1,437,787
Accumulated depreciation	(88,498)	(93,323)	(68,858)
Equipment, net	1,360,503	1,349,495	1,368,929
Computers, office equipment and software [Member]
Total equipment	14,800	23,709	18,678
Furniture and Fixtures [Member]
Total equipment	27,726	12,634	12,634
Product Development and Manufacturing Equipment [Member]
Total equipment	113,820	113,820	113,820
In process equipment [Member]
Total equipment	$ 1,292,655	$ 1,292,655	$ 1,292,655

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Purchase of equipment	$ (27,726)	$ (5,031)	$ (5,031)	$ (1,347,664)
Depreciation expense	5,782	6,684	24,465	$ 18,349
Initial payment of equipment			(1,292,655)
Estimated cost			$ 1,803,000
Cost of equipment description			The remaining $510,345 will be paid upon the completion of the equipment once the final specifications have been determined pending optimization of the Company’s product iteration specific to this equipment
Proceeds from Sales Assets	2,161
Vestal New York [Member]
Disposal of Fixd Assets	10,936
Proceeds from Sales Assets	2,161
Gain (Loss) on Disposition of Assets	$ 8,775

Debt (Details)

Debt (Details)	12 Months Ended
	Aug. 31, 2020USD ($)
Principal	$ 3,600,000
Debt Discount	(663,918)
Balance	2,936,082
Interest Payable	$ 1,523,943
March 2015 Loan as amended [Member]
Issue Date	Mar. 4, 2015
Maturity Date	Dec. 31, 2019
Principal	$ 600,000
Debt Discount
Balance	600,000
Interest Payable	$ 186,797
2013 Note as amended [Member]
Issue Date	Oct. 7, 2013
Maturity Date	Dec. 31, 2019
Principal	$ 3,000,000
Debt Discount	(663,918)
Balance	2,336,082
Interest Payable	$ 1,337,146

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Nov. 03, 2017	Nov. 03, 2017	Mar. 04, 2015	Oct. 07, 2013	Nov. 26, 2018	Aug. 31, 2020	Aug. 31, 2019
Accretion of debt discount							$ 663,918
Interest expense							128,239
Bridge Loan One [Member]
Proceeds from loan payable			$ 600,000
Interest rate			7.00%
Debt default, interest rate			15.00%
Third Amendment to 2013 Bridge Loan Agreement [Member] | Warrant [Member]
Debt instrument maturity date	Dec. 31, 2022
Third Amendment to 2013 Bridge Loan Agreement [Member] | Investor [Member]
Debt discount	$ 1,074,265	$ 1,074,265
Third Amendment to 2013 Bridge Loan Agreement [Member] | Third Amendment to the March 2015 Loan [Member] | Investor [Member]
Interest rate		10.50%
Debt instrument maturity date		Dec. 31, 2019
March 2015 Loan [Member]
Debt conversion converted instrument, shares issued					532,377
Debt conversion converted instrument, Amount					$ 798,566
Accrued interest					$ 7,922
March 2015 Loan as amended [Member]
Interest expense							19,691
Two Thousand Note As Amended [Member]
Interest expense							$ 108,548
Debt conversion converted instrument, shares issued					2,934,290
Debt conversion converted instrument, Amount					$ 4,401,434
Accrued interest					$ 44,260
2015 Bridge Loan Agreement [Member] | Investor [Member]
Interest rate	10.50%
Debt instrument maturity date	Dec. 31, 2019
Convertible Promissory Note [Member]
Proceeds from loan payable				$ 3,000,000
Interest rate				7.00%
Debt instrument, terms of conversion feature				The Investor may elect to convert principal and accrued interest into units of the Company's equity securities, with each Unit consisting of (a) one share of common stock; and (b) one Stock Purchase Warrant for the purchase of one share of common stock. The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company's common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Warrant being equal to 60% of the 20 day average closing price of the Company's common stock prior to conversion.

November 2018 Private Placeme_2

November 2018 Private Placement (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 26, 2018	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
November 2018 Private Placement units issued in exchange for convertible debt, Amount				$ 5,200,000
Interest payable to related party			$ 52,182
Estimated volatility rate		89.44%
Risk free interest rate		0.19%		1.84%
Expected life		4 years
November 2018 Private Placement [Member]
Issuance of common stock shares to purchase unit	16,666,667
Price per unit	$ 1.50
Unit price, description	Company’s equity securities at a price of $1.50 per Unit with each Unit comprised of (a) one share of common stock; and (b) one Series T Warrant to purchase one share of common stock at a price of $1.70 per share for a period of seven (7) years.
November 2018 Private Placement units issued, Shares	13,200,000
November 2018 Private Placement units issued, Amount	$ 19,800,000
November 2018 Private Placement units issued in exchange for convertible debt, Shares	3,466,667
November 2018 Private Placement units issued in exchange for convertible debt, Amount	$ 5,200,000
Number of shares unit exchange for cash	13,200,000
Relative fair value of common stock			13,687,151
Relative fair value of Series T Warrants			$ 11,312,849
Market price per share			$ 2.94
Estimated volatility rate			85.85%
Risk free interest rate			2.97%
Expected dividend rate			0.00%
Expected life			7 years
Kalen [Member] | November 2018 Private Placement [Member]
Capital corporation purchased units	13,100,000

Common Stock and Warrants (Deta

Common Stock and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Shares of Common Stock Issuable from Warrants	19,483,517	19,483,517	19,483,517
Weighted Average Exercise Price	$ 4.16	$ 4.16
Series M warrants [Member]
Shares of Common Stock Issuable from Warrants	246,000	246,000	246,000
Weighted Average Exercise Price	$ 2.34	$ 2.34
Expiration	Dec. 31, 2022	Dec. 31, 2022
Date of Issuance	Dec. 7, 2015	Dec. 7, 2015
Series N warrants [Member]
Shares of Common Stock Issuable from Warrants	767,000	767,000	767,000
Weighted Average Exercise Price	$ 3.38	$ 3.38
Expiration	Dec. 31, 2022	Dec. 31, 2022
Date of Issuance	Dec. 31, 2015	Dec. 31, 2015
Series P warrants [Member]
Shares of Common Stock Issuable from Warrants	213,500	213,500	213,500
Weighted Average Exercise Price	$ 3.70	$ 3.70
Expiration	Dec. 31, 2022	Dec. 31, 2022
Date of Issuance	Mar. 25, 2016	Mar. 25, 2016
Series R warrants [Member]
Shares of Common Stock Issuable from Warrants	468,750	468,750	468,750
Weighted Average Exercise Price	$ 4	$ 4
Expiration	Dec. 31, 2022	Dec. 31, 2022
Date of Issuance	Jun. 20, 2016	Jun. 20, 2016
Series S-A warrants [Member]
Shares of Common Stock Issuable from Warrants	300,000	300,000	300,000
Weighted Average Exercise Price	$ 2.53	$ 2.53
Expiration	Dec. 31, 2022	Dec. 31, 2022
Date of Issuance	Jul. 24, 2017	Jul. 24, 2017
Series S warrants [Member]
Shares of Common Stock Issuable from Warrants	821,600	821,600	821,600
Weighted Average Exercise Price	$ 3.42	$ 3.42
Expiration	Sep. 29, 2022	Sep. 29, 2022
Date of Issuance	Sep. 29, 2017	Sep. 29, 2017
Series T warrants [Member]
Shares of Common Stock Issuable from Warrants	16,666,667	16,666,667	16,666,667
Weighted Average Exercise Price	$ 1.70	$ 1.70
Expiration	Nov. 26, 2025	Nov. 26, 2025
Date of Issuance	Nov. 26, 2018	Nov. 26, 2018

Common Stock and Warrants (De_2

Common Stock and Warrants (Details Narrative) - $ / shares	12 Months Ended
	Aug. 31, 2019	Nov. 30, 2020	Aug. 31, 2020
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, shares issued	52,959,323	52,959,323	52,959,323
Common stock, shares outstanding	52,959,323	52,959,323	52,959,323
2006 Incentive Stock Option Plan [Member]
Reserved for issuance under long term incentive plan			6,036,685
2006 Incentive Stock Option Plan [Member] | October 10, 2006 [Member]
Reserved for issuance under long term incentive plan		5,734,277
November 2018 Private Placement [Member]
Shares issued under private placerment	16,666,667
Shares issued price per share	$ 1.50

Stock Options (Details)

Stock Options (Details) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Expected dividend yield
Expected stock price volatility	89.44%
Risk-free interest rate	0.19%			1.84%
Expected term (in years)	4 years
Exercise price	$ 3.42			$ 3.54
Weighted-average grant date fair-value	$ 2.16
Minimum [Member]
Expected stock price volatility		82.94%	82.94%	87.42%
Risk-free interest rate		1.40%	0.08%
Expected term (in years)		4 years 6 months	1 year 10 months 14 days	4 years 6 months
Exercise price		$ 2.32	$ 2.32
Weighted-average grant date fair-value		$ 1.61	$ 1.15	$ 2.35
Maximum [Member]
Expected stock price volatility		86.23%	99.44%	87.84%
Risk-free interest rate		1.69%	1.69%
Expected term (in years)		5 years 9 months	5 years 9 months	5 years
Exercise price		$ 3.54	$ 8
Weighted-average grant date fair-value		$ 1.55	$ 1.84	$ 2.43

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Number of Options
Outstanding Beginning	7,804,734
Outstanding Ending	7,817,234	7,804,734
Exercisable Ending	3,956,434	3,853,734
Weighted Average Exercise Price ($)
Weighted-average exercise price Beginning	$ 4.16
Grants	3.42		$ 3.54
Weighted-average exercise price Ending	4.16	$ 4.16
Exercisable Ending	$ 3.66	$ 3.64
Weighted Average Remaining Contractual Term
Outstanding Ending	5 years 3 months 15 days	5 years 6 months 14 days
Aggregate Intrinsic Value ($)
Outstanding Ending	$ 25,886,685	$ 3,030,518
Stock Option [Member]
Number of Options
Outstanding Beginning	7,804,734	2,777,334	1,291,334
Grants	50,000	5,158,000	1,506,000
Forfeitures and cancellations	(37,500)	(130,600)	(20,000)
Outstanding Ending	7,817,234	7,804,734	2,777,334
Exercisable Ending	3,956,434	3,853,734
Weighted Average Exercise Price ($)
Weighted-average exercise price Beginning	$ 4.16	$ 4.31	$ 5.22
Grants	3.42	4.06	3.54
Forfeitures and cancellations	3.54	3.54	4.87
Weighted-average exercise price Ending	4.16	4.16	$ 4.31
Exercisable Ending	$ 3.66	$ 3.64
Weighted Average Remaining Contractual Term
Outstanding Ending	5 years 3 months 15 days	5 years 6 months 14 days
Exercisable Ending	6 years 3 months 19 days	6 years 6 months 14 days
Aggregate Intrinsic Value ($)
Outstanding Ending	$ 27,557,385	$ 3,030,518
Exercisable Ending	$ 15,789,872	$ 1,526,908

Stock Options (Details 2)

Stock Options (Details 2) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Stock Compensation Expense:
Total stock based compensation expense	$ 1,838,532	$ 420,970	$ 4,872,909	$ 3,959,367
Stock Option [Member]
Stock Compensation Expense:
SG&A	1,533,824	172,219	3,788,538	2,993,532
R&D	304,708	248,751	1,084,371	965,835
Total stock based compensation expense	$ 1,838,532	$ 420,970	$ 4,872,909	$ 3,959,367

Stock Options (Details 3)

Stock Options (Details 3) - $ / shares	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Number of Shares Subject to Outstanding Options	7,817,234	7,804,734
Weighted average contractural life (years)	5 years 3 months 15 days	5 years 6 months 14 days
Weighted-average exercise price	$ 4.16	$ 4.16
Number of Shares Subject to options exercisable	3,956,434	3,853,734
Weighted average contractural life (years) of options exercisable	6 years 3 months 19 days	6 years 6 months 14 days
Weighted-average exercise price of options exercisable	$ 3.66	$ 3.64
$2.32 Per Share [Member]
Number of Shares Subject to Outstanding Options	2,500,000	153,000
Weighted average contractural life (years)	5 years 7 months 2 days	9 years 1 month 9 days
Weighted-average exercise price	$ 2.60	$ 2.32
Number of Shares Subject to options exercisable	1,250,000	42,500
Weighted average contractural life (years) of options exercisable	5 years 7 months 2 days	9 years 1 month 9 days
Weighted-average exercise price of options exercisable	$ 2.60	$ 2.32
$2.60 Per Share [Member]
Number of Shares Subject to Outstanding Options	7,500	2,500,000
Weighted average contractural life (years)	5 years 11 months 15 days	5 years 10 months 3 days
Weighted-average exercise price	$ 3.28	$ 2.6
Number of Shares Subject to options exercisable	7,500	1,250,000
Weighted average contractural life (years) of options exercisable	5 years 11 months 15 days	5 years 10 months 3 days
Weighted-average exercise price of options exercisable	$ 3.28	$ 2.6
$3.28 Per Share [Member]
Number of Shares Subject to Outstanding Options	50,000	7,500
Weighted average contractural life (years)	5 years 10 months 21 days	6 years 2 months 16 days
Weighted-average exercise price	$ 3.42	$ 3.28
Number of Shares Subject to options exercisable	12,500	7,500
Weighted average contractural life (years) of options exercisable	5 years 10 months 21 days	6 years 2 months 16 days
Weighted-average exercise price of options exercisable	$ 3.42	$ 3.28
$3.46 Per Share [Member]
Number of Shares Subject to Outstanding Options	35,000	35,000
Weighted average contractural life (years)	5 years 1 month 6 days	5 years 4 months 6 days
Weighted-average exercise price	$ 3.46	$ 3.46
Number of Shares Subject to options exercisable	35,000	35,000
Weighted average contractural life (years) of options exercisable	5 years 1 month 6 days	5 years 4 months 6 days
Weighted-average exercise price of options exercisable	$ 3.46	$ 3.46
$3.54 Per Share [Member]
Number of Shares Subject to Outstanding Options	1,342,900	1,380,400
Weighted average contractural life (years)	7 years 7 months 10 days	7 years 9 months 11 days
Weighted-average exercise price	$ 3.54	$ 3.54
Number of Shares Subject to options exercisable	1,140,350	1,125,900
Weighted average contractural life (years) of options exercisable	8 years 1 month 20 days	8 years 5 months 5 days
Weighted-average exercise price of options exercisable	$ 3.54	$ 3.54
$3.66 Per Share [Member]
Number of Shares Subject to Outstanding Options	1,000,000	1,000,000
Weighted average contractural life (years)	2 years 9 months	3 years
Weighted-average exercise price	$ 3.66	$ 3.66
Number of Shares Subject to options exercisable	500,000	500,000
Weighted average contractural life (years) of options exercisable	2 years 9 months	3 years
Weighted-average exercise price of options exercisable	$ 3.66	$ 3.66
$4.87 Per Share [Member]
Number of Shares Subject to Outstanding Options	187,500	187,500
Weighted average contractural life (years)	6 years 11 months 23 days	7 years 2 months 23 days
Weighted-average exercise price	$ 4.87	$ 4.87
Number of Shares Subject to options exercisable	187,500	187,500
Weighted average contractural life (years) of options exercisable	6 years 11 months 23 days	7 years 2 months 23 days
Weighted-average exercise price of options exercisable	$ 4.87	$ 4.87
$5.35 Per Share [Member]
Number of Shares Subject to Outstanding Options	1,008,000	1,008,000
Weighted average contractural life (years)	7 years 1 month 2 days	7 years 4 months 2 days
Weighted-average exercise price	$ 5.35	$ 5.35
Number of Shares Subject to options exercisable	735,000	672,000
Weighted average contractural life (years) of options exercisable	7 years 1 month 2 days	7 years 4 months 2 days
Weighted-average exercise price of options exercisable	$ 5.35	$ 5.35
$5.94 Per Share [Member]
Number of Shares Subject to Outstanding Options	33,334	33,334
Weighted average contractural life (years)	22 days	3 months 22 days
Weighted-average exercise price	$ 5.94	$ 5.94
Number of Shares Subject to options exercisable	33,334	33,334
Weighted average contractural life (years) of options exercisable	22 days	3 months 22 days
Weighted-average exercise price of options exercisable	$ 5.94	$ 5.94
$6.00 Per Share [Member]
Number of Shares Subject to Outstanding Options	800,000	800,000
Weighted average contractural life (years)	2 years 9 months	3 years
Weighted-average exercise price	$ 6	$ 6
Number of Shares Subject to options exercisable
Weighted average contractural life (years) of options exercisable	2 years 9 months	3 years
Weighted-average exercise price of options exercisable	$ 6	$ 6
$8.00 Per Share [Member]
Number of Shares Subject to Outstanding Options	700,000	700,000
Weighted average contractural life (years)	2 years 9 months	3 years
Weighted-average exercise price	$ 8	$ 8
Number of Shares Subject to options exercisable
Weighted average contractural life (years) of options exercisable	2 years 9 months	3 years
Weighted-average exercise price of options exercisable	$ 8	$ 8
$2.32 Per Share [Member]
Number of Shares Subject to Outstanding Options	153,000
Weighted average contractural life (years)	8 years 10 months 10 days
Weighted-average exercise price	$ 2.32
Number of Shares Subject to options exercisable	55,250
Weighted average contractural life (years) of options exercisable	8 years 10 months 10 days
Weighted-average exercise price of options exercisable	$ 2.32

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	Jul. 05, 2019	Oct. 09, 2019	Sep. 16, 2019	Nov. 30, 2020	Nov. 30, 2019	Jul. 02, 2020	Aug. 31, 2020	Aug. 31, 2019
Closing stock price				$ 7.65			$ 3.66
Aggregate intrinsic value of options, description							4,075,900 outstanding options have an exercise price below $3.66 per share
Aggregate intrinsic value of options				$ 25,886,685			$ 3,030,518
Aggregate intrinsic value of vested options							1,526,908
Share based compensation expenses not yet recognized				$ 5,297,826			$ 7,116,483
Share based compensation recognition period				3 years 9 months			4 years
Vesting term				6 years 3 months 19 days			6 years 6 months 14 days
Option outstanding				6,386,567
Option exercise price				$ 7.65
Aggregate intrinsic value of options vested				$ 14,070,872
Stock Option [Member]
Aggregate intrinsic value of options				$ 27,557,385			$ 3,030,518
Share based compensation							$ 58,367
Forfeitures				37,500			130,600	20,000
Stock options exercise price				$ 3.54			$ 3.54	$ 4.87
Stock Option [Member] | Director [Member]
Stock options granted				50,000
Stock options exercise price				$ 3.42
Option grant term				6 years
Stock Option [Member] | Employee [Member]
Stock options granted					153,000
Stock options exercise price					$ 2.32
Option grant term					10 years
Director and CEO [Member]
Stock options grant							2,500,000
Options granted, description							Options granted with an exercise price of $3.66 as to 1,000,000 options, $6.00 as to 800,000 options and $8.00 as to 700,000 options
Vesting rate description							500,000 on the date of grant, 800,000 on the six month anniversary, 700,000 on the one-year anniversary and 500,000 on the eighteen month anniversary
Vesting term							3 years
Jatinder S. Bhogal [Member]
Stock options grant						2,500,000
Stock options exercise price						$ 2.60
Vesting rate description						vesting as to 1,250,000 options and July 1, 2021 as to 1,250,000 options
Vesting term						6 years
Employee [Member]
Stock options grant		153,000
Stock options exercise price		$ 2.32
Vesting rate description		1/36th per month
Vesting term		10 years
Consultant [Member]
Stock options grant			5,000
Stock options exercise price			$ 3.54
Vesting rate description			1/20th per quarter
Vesting term			6 years
Directors and Employees [Member]
Stock options granted	498,000
Stock options exercise price	$ 3.54
Vesting rate description	1/20th per quarter
Vesting term	6 years
Director [Member]
Stock options granted	1,008,000
Stock options exercise price	$ 3.54
Vesting term	10 years
2006 Incentive Stock Option Plan [Member]
Stock options grant				15,000,000			15,000,000
Stock options available for grant, shares							6,036,685
Net shares issued pursuant to exercises of vested options (due to the cashless exercise feature)							629,677
Stock options exercised, total							1,305,001
Maturity date				Nov. 30, 2020			Feb. 7, 2021

Lease (Details)

Lease (Details) - USD ($)	3 Months Ended			12 Months Ended
	Nov. 30, 2020	[1]	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Notes to Financial Statements
Operating lease cost	$ 32,648		$ 6,666	$ 26,664	$ 8,888
Short-term lease costs
Total net lease costs	$ 32,648		$ 6,666	$ 26,664	$ 8,888
[1]	Represents 3 months of rent expense at $2,222 per month, $26,400 lease termination fee and ($418) of unrecognized interest expense.

Lease (Details 1)

Lease (Details 1) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Notes to Financial Statements
Operating lease right-of-use asset		$ 42,212	$ 65,646
Current maturities of operating lease		24,828	23,169
Non-current operating lease		17,737	42,564
Total operating lease liabilities		$ 42,564	$ 65,733
Weighted Average remaining lease term (in years):		1 year 8 months 2 days	2 years 10 months 25 days
Discount rate:			5.85%

Lease (Details 2)

Lease (Details 2) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	Aug. 31, 2019
Notes to Financial Statements
2021		$ 26,664
2022		18,128
Total lease payments		44,792
Less: Imputed interest		(2,228)
Total operating lease liabilities		42,564	$ 65,733
Less: current lease obligations		24,828	23,169
Long term lease obligations		$ 17,737	$ 42,564

Lease (Details Narrative)

Lease (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Lease Term	3 years	3 years
Lease description	The Lease has an initial term of three years through May 1, 2022 with monthly rent due of $2,200 for the first two years and $2,266 during year three.	The Lease has an initial term of three years through May 1, 2022 with monthly rent due of $2,200 for the first two years and $2,266 during year three. The Company has the sole option to renew the lease for an additional two years through May 1, 2024
Rent expense	$ 418
South Korea [Member]
Lease description		The lease has a term of one year from September 23, 2020 through September 23, 2021
Operating lease expenses		$ 1,200
Frequency of payment		Monthly

Transactions with Related Per_2

Transactions with Related Persons (Details Narrative) - USD ($)	Jul. 01, 2020	Dec. 02, 2018	Aug. 07, 2017	Nov. 26, 2018	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
November 2018 Private Placement units issued in exchange for convertible debt, Amount								$ 5,200,000
November 2018 Private Placement [Member]
Issuance of common stock shares to purchase unit				16,666,667
Price per unit				$ 1.50
Unit price, description				Company’s equity securities at a price of $1.50 per Unit with each Unit comprised of (a) one share of common stock; and (b) one Series T Warrant to purchase one share of common stock at a price of $1.70 per share for a period of seven (7) years.
November 2018 Private Placement units issued in exchange for convertible debt, Shares				3,466,667
November 2018 Private Placement units issued in exchange for convertible debt, Amount				$ 5,200,000
November 2018 Private Placement units issued, Amount				$ 19,800,000
Talia Jevan Properties, Inc [Member]
Related party payable					$ 0		$ 53,251
Proceeds from related party debt					0	$ 73,005	210,415	15,497
Repayment of related party debt					53,251	0	172,661	0
Mr. Bhogal [Member]
Related party payable					34,167		48,758
Mr. Bhogal [Member] | Consulting Agreement [Member]
Share-based Compensation (monthly)	$ 34,167	$ 5,000	$ 18,750
Related party expense					102,500	56,250	$ 255,833	183,750
Satterlee [Member]
Legal services					$ 43,750	$ 43,750		$ 3,480
Kalen [Member] | November 2018 Private Placement [Member]
Units purchased in exchange for cash				13,100,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 6,598,870	$ 5,901,666
Capitalized research and development	1,069,124	1,014,380
Depreciation	1,762	(7,353)
Stock based compensation	3,006,736	1,983,425
Research and development credit carry forward	657,737	599,646
Total deferred tax assets	11,334,229	9,491,764
Less: valuation allowance	(11,334,229)	(9,491,764)
Net deferred tax asset

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Income Taxes Details Abstract
Income tax benefit at statutory rate	$ 1,544,143	$ 1,446,412
Permanent differences	240,231	69,190
Research and development credit	58,091	78,981
Change in valuation allowance	(1,842,465)	(1,594,583)
Total

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Income Taxes Details Abstract
Change in valuation allowance	$ (1,842,465)	$ (1,594,583)
Research and development credit carry forward	657,737	$ 599,646
Federal income tax	$ 31,423,193
Corporate tax rate	21.00%	35.00%
Uncertain tax positions	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Aug. 31, 2020USD ($)
Lease description	Term from May 1, 2019 through May 1, 2022 with monthly rent due of $2,200 for the first two years and $2,266 during year three
Estimated cost	$ 1,803,000
Cost of equipment description	The remaining $510,345 will be paid upon the completion of the equipment once the final specifications have been determined pending optimization of the Company’s product iteration specific to this equipment
South Korea [Member]
Lease description	The lease has a term of one year from September 23, 2020 through September 23, 2021.
Operating lease expenses	$ 1,200
Frequency of payment	Monthly

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020	Aug. 31, 2019
Numerator:
Loss available to common stockholders'	$ (2,537,035)	$ (1,105,278)	$ (7,353,062)	$ (6,887,678)
Denominator:
Weighted average number of common shares outstanding	52,959,323	52,959,323	52,959,323	48,686,720
Basic and diluted EPS	$ (0.05)	$ (0.02)	$ (0.14)	$ (0.14)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options	7,817,234	2,935,334	7,804,734	2,777,334
Warrants	19,483,517	19,483,517	19,483,517	19,483,517
Total shares not included in the computation of diluted losses per share	27,300,751	22,418,851	27,288,251	22,260,851

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jul. 05, 2019	Dec. 18, 2020	Oct. 26, 2020	Oct. 20, 2020	Oct. 19, 2020
Director [Member]
Stock options exercise price	$ 3.54
SolarWindow Asia Co [Member]
Capital contribution to subsidiary			$ 78,000
Additional contribution to subsidiary			$ 753,000
Talia Jevan Properties, Inc [Member]
Repayment of related party debt				$ 53,251
Joesph Sierchio [Member]
Options granted to related party					50,000
Stock options exercise price					$ 3.42
Options vested, description					Vest as to 12,500 immediately and 12,500 each anniversary thereafter and expires on October 19, 2026
Subsequent Event [Member] | John Conklin
Common stock cancelled		1,008,000
Subsequent Event [Member] | Director [Member]
Stock options exercised		16,667
Issuance of restricted common stock		5,667